4-oxo-N-(4-hydroxyphenyl)retinamide: Two independent ways to kill cancer cells

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Tiberio, Paola ^a   Cavadini, Elena ^a   Abolafio, Gabriella ^a   Formelli, Franca ^a   Appierto, Valentina ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 OXO N (4 HYDROXYPHENYL)RETINAMIDE; ANTINEOPLASTIC AGENT; GROWTH DIFFERENTIATION FACTOR 15; PROTEIN BCL 2; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 4 OXOFENRETINIDE; 4-OXOFENRETINIDE; DRUG DERIVATIVE; FENRETINIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; MITOSIS INHIBITION; NEUROBLASTOMA; OVARY CANCER; OXIDATIVE STRESS; UTERINE CERVIX CANCER; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; FENRETINIDE; HUMANS; MAP KINASE KINASE 4; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 78149421526     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013362     Document Type: Article

References (35)

1. Nagy L, Thomazy VA, Heyman RA, Davies PJ (1998) Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ 5: 11-19.
2. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, et al. (1999) Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847-1856.
3. Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, et al. (2005) Randomized trial of fenretinide (4HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 115: 625-629.
4. Moglia D, Formelli F, Baliva G, Bono A, Accetturi M, et al. (1996) Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Cancer Lett 110: 87-91.
5. Tradati N, Chiesa F, Rossi N, Grigolato R, Formelli F, et al. (1994) Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4- HPR). Cancer Lett 76: 109-111.
6. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, et al. (2006) Fifteenyear results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17: 1065-1071.
7. De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, et al. (2002) Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 86: 24-27.
8. Hail N, Jr., Kim HJ, Lotan R (2006) Mechanisms of fenretinide-induced apoptosis. Apoptosis 11: 1677-1694.
9. Appierto V, Tiberio P, Villani MG, Cavadini E, Formelli F (2009) PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 30: 824-831.
10. Appierto V, Villani MG, Cavadini E, Gariboldi M, De Cecco L, et al. (2007) Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells. Oncogene 26: 3952-3962.
11. Villani MG, Appierto V, Cavadini E, Valsecchi M, Sonnino S, et al. (2004) Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res 10: 6265-6275.
12. Villani MG, Appierto V, Cavadini E, Bettiga A, Prinetti A, et al. (2006) 4-oxofenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res 66: 3238-3247.
13. Appierto V, Tiberio P, Cavadini E, Casalini P, Cappelletti G, et al. (2009) Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity. Mol Cancer Ther 8: 3360-3368.
14. Wu J, Kaufman RJ (2006) From acute ER stress to physiological role of the Unfolded Protein Response. Cell Death Differ 13: 374-384.
15. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP (2008) Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100: 580-595.
16. Reed JC (1999) Fenretinide: the death of a tumor cell. J Natl Cancer Inst 91: 1099-1100.
17. Delia D, Aiello A, Formelli F, Fontanella E, Costa A, et al. (1995) Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood 85: 359-367.
18. Lee SH, Krisanapun C, Baek SJ (2010) NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3. Carcinogenesis 31: 719-728.
19. Jutooru I, Chadalapaka G, Chintharlapalli S, Papineni S, Safe S (2009) Induction of apoptosis and nonsteroidal anti-inflammatory drug-activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative. Mol Carcinog 48: 692-702.
20. Yoshioka H, Kamitani H, Watanabe T, Eling TE (2008) Nonsteroidal antiinflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem 283: 33129-33137.
21. Shim M, Eling TE (2008) Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism. Mol Cancer Ther 7: 961-971.
22. Valsecchi M, Aureli M, Mauri L, Illuzzi G, Chigorno V, et al. (2010) Sphingolipidomics of A2780 human ovarian carcinoma cells treated with synthetic retinoids. J Lipid Res 51: 1832-1840.
23. Sgadari C, Toschi E, Palladino C, Barillari G, Carlei D, et al. (2000) Mechanism of paclitaxel activity in Kaposi's sarcoma. J Immunol 165: 509-517.
24. Bourgarel-Rey V, Savry A, Hua G, Carré M, Bressin C, et al. (2009) Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Biochem Pharmacol 78: 1148-1156.
25. Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, et al. (2001) Accompanying protein alterations in malignant cells with a microtubulepolymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem Pharmacol 62: 1469-1480.
26. Chua YS, Chua YL, Hagen T (2010) Structure activity analysis of 2- methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Mol Cancer Ther 9: 224-235.
27. Rubio S, Quintana J, Eiroa JL, Triana J, Estévez F (2010) Betuletol 3-methyl ether induces G(2)-M phase arrest and activates the sphingomyelin and MAPK pathways in human leukemia cells. Mol Carcinog 49: 32-43.
28. Ting CM, Lee YM, Wong CK, Wong AS, Lung HL, et al. (2010) 2- Methoxyestradiol induces endoreduplication through the induction of mitochondrial oxidative stress and the activation of MAPK signaling pathways. Biochem Pharmacol 79: 825-841.
29. Durrant D, Richards JE, Walker WT, Baker KA, Simoni D, et al. (2008) Mechanism of cell death induced by cis-3, 49, 5-trimethoxy-39-aminostilbene in ovarian cancer. Gynecol Oncol 110: 110-117.
30. Khawaja NR, Carré M, Kovacic H, Estève MA, Braguer D (2008) Patupiloneinduced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol Pharmacol 74: 1072-1083.
31. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67: 3512-3517.
32. Alexandre J, Batteux F, Nicco C, Chéreau C, Laurent A, et al. (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxelinduced cancer cell death both in vitro and in vivo. Int J Cancer 119: 41-48.
33. Pignatelli M, Sánchez-Rodríguez J, Santos A, Perez-Castillo A (2005) 15-deoxy- Delta-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. Carcinogenesis 26: 81-92.
34. Appierto V, Villani MG, Cavadini E, Lotan R, Vinson C, et al. (2004) Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ 1: 270-279.
35. Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, et al. (2004) CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 18: 3066-3077.